Description

Tregalizumab (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023

Summary

Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.

Tregalizumab, also known as BT-061, is a humanized mAb against the CD4 receptor. It works specifically on the immunoglobulin G (IgG)-like C2 type 1 domain of the CD4 receptor in Treg cells, inducing downstream phosphorylation events, leading to the activation of this important regulatory cell. The activation of Treg cells thus reduces the damaging effects of cytokines and T effector cells in active RA.

View Full Report at http://www.marketresearchreports.biz/analysis/247167

Scope

- Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Tregalizumab including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Tregalizumab for the top 6 countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain and the UK.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid Arthritis.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of Tregalizumab performance.
- Obtain sales forecast for Tregalizumab from 2013-2023 in top 6 countries (the US, France, Germany, Italy, Spain and the UK).

Download Detail Report With Complete TOC at
http://www.marketresearchreports.biz/sample/sample/247167

Table of Content

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 11
2.3 Upcoming Related Reports 14
3 Disease Overview 15
3.1 Etiology and Pathophysiology 15
3.1.1 Etiology 15
3.1.2 Pathophysiology 15
3.2 Symptoms 20
3.3 Prognosis 21
3.4 Quality of Life 21
4 Disease Management 22
4.1 Diagnosis and Treatment Overview 22
4.1.1 Diagnosis 22
4.1.2 Treatment Guidelines 24
4.1.3 Leading Prescribed Drugs for the Treatment of RA 34
4.1.4 Clinical Practice 35
5 Competitive Assessment 41
5.1 Overview 41
6 Unmet Need and Opportunity 43
6.1 Overview 43
6.2 Development of Cost-Effective Therapies 44
6.2.1 Unmet Need 44
6.2.2 Gap Analysis 45
6.2.3 Opportunity 45
7 Pipeline Assessment 55
7.1 Overview 55

Browse Latest News at http://www.marketresearchreports.biz/articles



About Us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Browse Our Press Releases by Prnewswire: http://www.prnewswire.com/news/marketresearchreports.biz